Showing results (101-110 of 230) with videos related to

Sort By:
Pageof 23
Plos Biology|August 30, 2018
BRAF and AXL oncogenes drive RIPK3 expression loss in cancerAyaz Najafov, Ioannis K Zervantonakis, Adnan K Mookhtiar, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2020
Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 casesDavid B Chapel, Elizabeth K Lee, Annacarolina F L Da Silva, et al.
Plos One|November 23, 2013
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutationsNicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, et al.
Gynecologic Oncology|July 10, 2012
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinomaUrsula A Matulonis, Sudarshan Sharma, Sharad Ghamande, et al.
JMIR Cancer|March 10, 2025
Usability, Acceptability, and Barriers to Implementation of a Collaborative Agenda-Setting Intervention (CASI) to Promote Person-Centered Ovarian Cancer Care: Development StudyRachel A Pozzar, James A Tulsky, Donna L Berry, et al.
The Veterinary Clinics of North America. Food Animal Practice|March 1, 2012
Evidence-based early clinical detection of emerging diseases in food animals and zoonoses: two casesClaude Saegerman, Marie-France Humblet, Sarah Rebecca Porter, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2013
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancerJoyce F Liu, Sara M Tolaney, Michael Birrer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2014
Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancerElizabeth Pham, Michael J Birrer, Scott Eliasof, et al.
Gynecologic Oncology|February 3, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerLucy Gilbert, Ana Oaknin, Ursula A Matulonis, et al.
Medical Acupuncture|April 25, 2014
The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled TrialWeidong Lu, Ursula A Matulonis, Julie E Dunn, et al.
Pageof 23